CBMG shows strong data in early CART trials
This article was originally published in Scrip
You may also be interested in...
CBMG exec Tony Liu looks to differentiate CAR-T offerings partly based on ability to produce at a large scale in China, at a standard that matches the US.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.